One MedImmune Way
6 articles with Viela Bio
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
Designation based on positive primary analysis of pivotal study, N-MOmentum
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Viela Bio Announces Inebilizumab Achieved Primary and Key Secondary Endpoints in Pivotal Trial in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Largest controlled monotherapy trial in NMOSD demonstrates reduction in risk of attacks and reduction in worsening of disability in patients treated with inebilizumab
Viela Bio, based in Gaithersburg, Md., announced that N-MOmentum, its Phase IIb pivotal trial of inebilizumab, met both primary and key secondary endpoints in neuromyelitis optica spectrum disorder (NMOSD).